Research libraryTesting and sourcing
The Most Popular Peptides in Research
For laboratory research use only. The compounds discussed here are sold strictly for in vitro research. They are not drugs, supplements or cosmetics and are not for human or animal use. This article summarizes published literature for reference and is not medical or usage advice.
“Popular peptides” hides a lot under three words. A peptide can dominate the literature because the chemistry to make it finally got good. Or because it sits on a receptor everyone cares about. Or, honestly, just because it has been kicking around long enough to pile up citations. Below we run through the classes you bump into most, what each actually is down at the molecule, and the synthesis tricks that made them easy to get. No breathless claims, just what the papers back up.
Key findings
- More than 80 peptide drugs have reached the market since insulin, and over 150 were in active development as of a 2021 review, which is why so many peptide classes are “popular” to study [1][2].
- Antimicrobial peptides are a huge, well-studied family found across animals and plants, built as broad-spectrum host-defense molecules [3].
- Cell-penetrating peptides trace back to the 1988 discovery that the HIV tat protein could cross into cultured cells [4].
- GLP-1 analogues like semaglutide are engineered peptides: two substitutions on human GLP-1 plus a fatty-acid modification pushed the plasma half-life to about 46 hours in mini-pigs [5].
- The tripeptide copper complex GHK-Cu is a small, old favorite, with its copper binding and a fibroblast collagen effect both measured decades ago [6].
Why some peptides get all the attention
Peptides are short amino-acid chains joined by peptide bonds, bigger than a typical drug molecule and smaller than a protein. Why do a few of them hog the spotlight? No mystery, really. Muttenthaler’s group, writing in 2021, tallied up more than 80 approved peptide drugs spread across a wide range of indications, and pointed out that fresh candidates keep flowing into the clinic [1]. An earlier survey by Lau and Dunn put over 150 peptides in active development and tracked how discovery moved beyond copying human hormones toward peptides from other natural sources and from medicinal chemistry [2].
So “popular” usually means one of two things: a peptide that became a drug and dragged a research literature along with it, or a structural class broad enough that thousands of labs poke at it. The categories below are the ones you’ll trip over most.
Antimicrobial peptides
Count by raw paper volume and antimicrobial peptides (AMPs) are tough to beat. Zasloff’s 2002 Nature review spelled out why they turn up all over biology. Animals and plants both carry potent, broad-spectrum peptides that beat back bacteria, fungi, viruses and protozoa, which is how an insect manages without antibodies and how a cornea stays clear [3]. Short, usually cationic, and most of them go after microbial membranes.
Small, broadly active, naturally occurring: that mix is catnip for researchers, and more so every year that antibiotic resistance ticks up. Cecropins, defensins, magainins, the list runs long, and people keep dredging new ones out of marine organisms and other odd places.
Cell-penetrating peptides
Cell-penetrating peptides (CPPs) are another busy corner, and their origin story is tidy. Back in 1988 Frankel and Pabo noticed the tat protein from HIV-1 getting taken up by cultured cells and then switching the viral promoter on, with uptake climbing when they added chloroquine [4]. That one observation, proteins can basically walk into cells, kicked off an entire subfield around short sequences that haul cargo across membranes.
The appeal is obvious: lots of interesting molecules can’t get into cells on their own, and a CPP is a possible shuttle. That keeps the class perpetually busy.
GLP-1 analogues and other engineered peptides
Some popular peptides are popular precisely because someone engineered them hard. Semaglutide is the textbook case. Lau and colleagues described its design in 2015: start from human GLP-1, make two amino acid substitutions (Aib at position 8, Arg at 34), and attach a fatty-acid chain at lysine 26 to boost albumin binding [5]. The payoff was durability. The plasma half-life came out near 46 hours in mini-pigs, a world away from the few minutes a native peptide hormone usually survives [5].
That kind of half-life extension is a recurring theme across engineered peptides. Werle and Bernkop-Schnurch reviewed the toolkit in 2006, covering tricks like swapping L-amino acids for D-amino acids, trimming the sequence, and PEGylation, and noted that octreotide, a shortened somatostatin analogue, lasts about 1.5 hours versus somatostatin’s few minutes [7]. Staying power is often what separates a lab curiosity from a widely used compound.
Copper peptides: GHK-Cu
Popular doesn’t have to mean new or large. Take GHK-Cu, the copper complex of the tripeptide glycyl-L-histidyl-L-lysine. It has been in the literature since the 1980s and it still crops up everywhere. Lau and Sarkar worked out its copper binding in 1981 and found the peptide competing with albumin for Cu(II) [6]. Maquart and colleagues then measured a collagen-synthesis effect in fibroblast cultures in 1988, with the response appearing at very low concentrations and independent of cell number [8].
Three amino acids plus a metal ion, and decades of follow-up work. Proof enough that popular and complicated are not the same word.
| Class | What it is | Why it’s studied so much |
|---|---|---|
| Antimicrobial peptides | Short, often cationic host-defense peptides [3] | Broad activity, antibiotic-resistance pressure |
| Cell-penetrating peptides | Sequences that cross cell membranes [4] | Potential cargo delivery across membranes |
| GLP-1 analogues | Engineered incretin peptides [5] | Receptor relevance plus long half-life |
| Copper peptides (GHK-Cu) | Tripeptide-copper complex [6][8] | Simple structure, long paper trail |
The synthesis behind the boom
None of this would be common without the chemistry to make peptides reliably. Merrifield’s solid-phase peptide synthesis, introduced in 1963, let chains be built one residue at a time on a resin, and the field exploded from there, as Chandrudu and colleagues recounted in their 2013 review [9]. The early step-by-step method had a catch: purity fell as the number of couplings rose. Boc and Fmoc protecting groups and better reagents chipped away at that problem.
Two later advances widened the door. Dawson and Kent’s 1994 native chemical ligation let two unprotected peptide fragments join at a native peptide bond, which made larger synthetic proteins practical [10]. And Bray’s 2003 account of manufacturing the 36-residue drug enfuvirtide showed chemical synthesis could scale to commercial volumes [11]. Put those together and you can see why so many peptides moved from “theoretically interesting” to “sitting on a shelf.”
FAQ
What makes a peptide “popular” in research?
Usually either it became a drug and pulled a literature along with it, or it belongs to a broad structural class like antimicrobial or cell-penetrating peptides that many labs study [1][3][4].
Why are GLP-1 analogues engineered rather than natural?
Native GLP-1 clears in minutes. Substitutions and a fatty-acid modification pushed semaglutide’s half-life to around 46 hours in mini-pigs, which is what makes it practical [5].
Is GHK-Cu really just three amino acids?
Yes. It’s glycyl-L-histidyl-L-lysine bound to copper(II), and its copper chemistry and a fibroblast collagen effect were both measured decades ago [6][8].
References
- Muttenthaler M, King GF, Adams DJ, Alewood PF. Trends in peptide drug discovery. Nat Rev Drug Discov. 2021. PMID 33536635
- Lau JL, Dunn MK. Therapeutic peptides: Historical perspectives, current development trends, and future directions. Bioorg Med Chem. 2018. PMID 28720325
- Zasloff M. Antimicrobial peptides of multicellular organisms. Nature. 2002. PMID 11807545
- Frankel AD, Pabo CO. Cellular uptake of the tat protein from human immunodeficiency virus. Cell. 1988. PMID 2849510
- Lau J, Bloch P, Schäffer L, et al. Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. J Med Chem. 2015. PMID 26308095
- Lau SJ, Sarkar B. The interaction of copper(II) and glycyl-L-histidyl-L-lysine, a growth-modulating tripeptide from plasma. Biochem J. 1981. PMID 7340824
- Werle M, Bernkop-Schnürch A. Strategies to improve plasma half life time of peptide and protein drugs. Amino Acids. 2006. PMID 16622600
- Maquart FX, Pickart L, Laurent M, Gillery P, Monboisse JC, Borel JP. Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. FEBS Lett. 1988. PMID 3169264
- Chandrudu S, Simerska P, Toth I. Chemical methods for peptide and protein production. Molecules. 2013. PMID 23584057
- Dawson PE, Muir TW, Clark-Lewis I, Kent SB. Synthesis of proteins by native chemical ligation. Science. 1994. PMID 7973629
- Bray BL. Large-scale manufacture of peptide therapeutics by chemical synthesis. Nat Rev Drug Discov. 2003. PMID 12815383